NEW YORK (Reuters Health) - A study of nearly 1,500 patients treated for kidney cancer at the University of California-Los Angeles in the last 15 years indicates that patients may benefit from an individualized treatment approach.
The one-size-fits-all treatment approach traditionally used for kidney cancer should be changed based on the results of this study, the researchers say.
Read the rest of this entry…
CHICAGO, Sept. 29 — For patients with metastatic kidney cancer, anti-angiogenesis therapy with sunitinib (Sutent) was more effective in those who had had cytoreductive surgery than in those who did not, researchers said here.
Read the rest of this entry…
Argos Therapeutics has initiated a Phase IIa trial of its AGS-003 therapy, in combination with sunitinib, for the treatment of newly diagnosed advanced renal cell carcinoma.
Approximately 50 subjects with advanced renal cell carcinoma (RCC) will be enrolled in the Phase IIa trial. The study will be conducted at up to 15 sites in North America.
Read the rest of this entry…
NEW YORK AUG 21, 2008 (Reuters Health) - Being active during adolescence and in adulthood appears to reduce the likelihood of developing kidney cancer later in life, a study shows.
Dr. Steven C. Moore of the National Cancer Institute in Bethesda, Maryland and colleagues analyzed data on nearly half a million people aged 50 to 71 who responded to a survey about their diet and level of physical activity, currently and in their teen years.
Read the rest of this entry…
Chicago - Retired PepsiCo executive David Scherb was in bad shape 15 months ago. Kidney cancer had spread to his lungs and one tumor became so big it ate through his sternum and bulged right through the surface of his skin. It was so painful he couldn’t wear a shirt.But last April, he started on a clinical trial of a new experimental kidney cancer drug from Novartis called RAD001. The pain declined, and by summer of 2007 the tumor was no longer visible. A full year later, the tumor remains in check. “If it wasn’t for this drug, I don’t feel like I would be here,” Scherb says.
Read the rest of this entry…